Bristol-Myers Squibb Reports Strong Q2 Earnings and Raises Full-Year Guidance
In the second quarter of 2026, Bristol-Myers Squibb (BMY) reported total revenues of $13 billion, a 6% increase year-over-year driven by strong performance in its growth portfolio. The company raised its full-year revenue guidance to between $49 billion and $50 billion from the previous range of $46 billion to $47.5 billion due to robust momentum across key products like Eliquis and Breyanzi. Non-GAAP diluted earnings per share (EPS) came in at $2.04, up significantly from $1.46 a year ago. The growth portfolio now accounts for nearly 60% of total revenue with sales reaching $7.6 billion, reflecting a 14% increase ex-FX. Eliquis saw particularly strong demand and share gains, generating $4.5 billion in Q2 revenues—a 21% rise—and the company raised its annual growth guidance to between 20% and 25%. BMY also highlighted progress on several key drug launches including Opdivo Qvantig, which saw a significant revenue jump from $30 million last year. The firm is preparing for future milestones such as regulatory decisions in late 2026 and early 2027.
Tickers: $BMY